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Comparative analysis of prognostic histopathologic parameters in subtypes of epithelioid
pleural mesothelioma
Aims: Malignant pleural mesothelioma (MPM) is a
rare malignancy with a dismal prognosis. While the
epithelioid type is associated with a more favourable
outcome, additional factors are needed to further
stratify prognosis and to identify patients who can
benefit from multimodal treatment. As epithelioid
MPM shows remarkable morphological variability,
the prognostic role of the five defined morphologies,
the impact of the nuclear grading system and the
mitosis-necrosis score were investigated in this study.
Methods and results: Tumour specimens of 192
patients with epithelioid MPM from five European
centres were histologically subtyped. Nuclear grading
and mitosis–necrosis score were determined and cor-
related with clinicopathological parameters and over-
all survival (OS). Digital slides of 55 independent
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cases from The Cancer Genome Atlas (TCGA) data-
base were evaluated for external validation. Histologi-
cal subtypes were collapsed into three groups based
on their overlapping survival curves. The tubulopapil-
lary/microcystic group had a significantly longer OS
than the solid/trabecular group (732 days versus
397 days, P = 0.0013). Pleomorphic tumours had
the shortest OS (173 days). The solid/trabecular vari-
ants showed a significant association with high
nuclear grade and mitosis–necrosis score. The mito-
sis–necrosis score was a robust and independent
prognostic factor in our patient cohort. The prognos-
tic significance of all three parameters was externally
validated in the TCGA cohort. Patients with tubu-
lopapillary or microcystic tumours showed a greater
improvement in OS after receiving multimodal ther-
apy than those with solid or trabecular tumours.
Conclusions: Histological subtypes of epithelioid MPM
have a prognostic impact, and might help to select
patients for intensive multimodal treatment
approaches.
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Introduction
Malignant pleural mesothelioma (MPM) is the most
common primary malignancy of the pleura. Due to
its highly aggressive clinical behaviour it confers a
dismal prognosis.1 MPM is divided into three major
histological types; namely, epithelioid, sarcomatoid
and biphasic.2 Histological type is an important prog-
nostic factor, also playing a substantial role in treat-
ment decision-making.3–5 The epithelioid type is the
most common type of MPM with the most favourable
prognosis.6 However, it is a heterogeneous entity and
there is a lack of morphological prognostic factors for
further stratification of epithelioid MPM (eMPM).
The presence of necrosis, the degree of nuclear aty-
pia and mitotic count have been shown to have a prog-
nostic role in eMPM.7–9 Furthermore, the presence of
prominent nucleoli and atypical mitotic figures was
found to be of prognostic value, while intranuclear
inclusions or a high nuclear/cytoplasmic ratio was not
associated with worse patients’ outcomes, and the
prognostic impact of chromatin structure alterations
remains unclear.7,9 Immunohistochemical assessment
of proliferation by Ki67 labelling was also shown to
have a prognostic role in eMPM when using 10% or
15% as cut-off values.7,10 Furthermore, composite
scores have been proposed and regarded as robust tools
in the stratification of patient outcome.11 The nuclear
grade is based on a three-tier assessment of nuclear
atypia and mitotic count.7,8 Rosen et al. developed the
mitosis–necrosis score (M/N score), which includes the
presence of necrosis and a two-tier scoring of mitotic
counts.8 A more complex pathological grading system
based on the presence of necrosis, the main histological
subtype, Ki67 proliferation index and a four-tier evalu-
ation of the mitotic count has also been developed for
risk stratification of eMPM.12
There are limited data on the prognostic implications of
histological subtypes in eMPM, but it is a promising
emerging marker for predicting patient outcome, simi-
larly to peritoneal mesothelioma13,14 and other malig-
nancies, such as lung,15–17 gastric18 and bladder
cancer.19 The pleomorphic subtype has been shown to be
a significant predictor of negative clinical outcome,20–24
while the microcystic/myxoid variant might have a posi-
tive impact on overall survival (OS) for eMPM patients.22
A predominantly solid morphological subtype has been
associated with worse outcome compared to non-solid
subtypes; however, it was not found to be an independent
prognostic factor.8 The role of other individual architec-
tural subtypes such as trabecular, tubulopapillary, micro-
cystic and micropapillary are yet to be determined.2
Accordingly, we investigated the prognostic impact
of five histological subtypes of eMPM and their associ-
ation with the other proposed histopathological prog-
nosticators, namely nuclear grade composed of scores
for nuclear atypia and mitotic count7 and the M/N
score based on the presence of necrosis and mitotic
count.8 Finally, we examined the association between
OS and histological subtypes in subgroups of patients
receiving multimodal therapy versus chemotherapy
or best supportive care-only regimens.
Materials and methods
S T U D Y C O H O R T
Our multicentre cohort consisted of a total of 192
patients diagnosed with eMPM between 1994 and
2015 at the Medical University of Vienna, Vienna,
Austria (n = 54), between 2000 and 2007 at the
National Koranyi Institute of TB and Pulmonology,
Budapest, Hungary (n = 30), between 2007 and 2012
at the University Clinic of Respiratory and Allergic
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Diseases, Golnik, Slovenia (n = 67), between 2013 and
2014 at the University of Zagreb, School of Medicine,
Jordanovac, Croatia (n = 9) and between 2016 and
2018 at the University Medicine Essen – Ruhrland-
klinik, Essen, Germany (n = 32). The pathological
diagnosis of eMPM was made by expert pulmonary
pathologists following international histological and
immunohistochemical criteria requiring a minimum of
two positive mesothelial markers (calretinin, WT-1,
D2-40, CK5/6) and at least two negative markers for
carcinoma (such as Ber-EP4, TTF-1, CEA). Clinical
data, including patients’ age, gender, date of diagnosis
and date of death or last contact, were collected in
accordance with each institute’s ethical guidelines and
the latest Declaration of Helsinki. The retrospective
analysis of MPM patients was approved in all partici-
pating centres by the local ethics committees at the
Medical University of Vienna (no. 904/2009), the
University Hospital Center Zagreb (no. 02/21AG) and
at the University Medicine Essen (17-7773-BO). The
Institutional Review Boards of the University Clinic
Golnik and the National Koranyi Institute of Tubercu-
losis and Pulmonology granted a waiver for the retro-
spective analyses. Samples were obtained by video-
assisted thoracoscopy (n = 106), percutaneous pleural
needle core biopsy (n = 28) or pleurectomy (n = 28).
In 30 cases the exact surgical sampling method was
not specified. All tissue samples were formalin-fixed
and paraffin-embedded (FFPE).
V A L I D A T I O N C O H O R T
We analysed 55 digital images of eMPMs openly avail-
able at the Cancer Digital Slide Archive (CDSA), which
correspond to diagnostic sections of specimens submitted
by tissue source sites of The Cancer Genome Atlas
(TCGA).25 Of these 55 sections, six were frozen sections
and 49 were FFPE specimens. Corresponding clinical
variables and survival data collected by TCGA Research
Network26 were downloaded from the cBioPortal.27
E V A L U A T I O N O F H I S T O P A T H O L O G I C A L F E A T U R E S
One haematoxylin and eosin (H&E)-stained slide was
provided for each case by expert pathologists from
the participating centres and was classified by A.B.
and L.B. Eventual discrepant cases were discussed
together and consensus was reached. Classification
was based on the predominant growth pattern and
on the presence of pleomorphic cytological features
(Figure 1).2,20,28 A sample was assigned pleomorphic
if at least 10% of the tumour area consisted of
anaplastic or giant tumour cells.20
Briefly, the following morphological features were
used for the classification.28 Tubulopapillary pattern
was defined by a combination of either tubular and/
or papillary structures consisting of cuboidal, slightly
enlarged tumour cells arranged around connective
tissue cores. Solid pattern was characterised by
tumour cells of epithelioid appearance forming larger
sheets or nests. Samples consisting of one or two lay-
ers of relatively small, monomorphic cells forming
thin cords often spreading within abundant desmo-
plastic stroma were assigned trabecular pattern.
Microcystic pattern was characterised by tumour cells
forming small cyst-like structures, while micropapil-
lary pattern exhibited small papillae without the
fibrovascular cores seen in tubulopapillary pattern.
Mitotic figures were counted in hot-spots at 9400
magnification and given as an average of mitotic fig-
ures per 10 high-power fields (Figure 2A,B).8 The
presence or absence of necrosis in the sample was
also evaluated and used to calculate M/N score (0–2),
as proposed earlier (Figure 2C).8 A composite nuclear
grade was calculated for each case based on nuclear
atypia and mitotic count scores evaluated according
to previous studies (Figure 2D–F).7,8
S T A T I S T I C A L A N A L Y S I S
OS was defined as the time from diagnosis to date of
death or for censored patients as the time between
diagnosis and date of last contact. The Kaplan–Meier
method and log-rank (Mantel–Cox) tests were used to
estimate OS and to calculate survival differences
between groups, respectively. A multivariate Cox
regression model including histology, M/N score and
nuclear grade as variables was calculated to identify
independent prognostic factors, hazard ratios (HR)
and their corresponding 95% confidence intervals
(CI). Fisher’s exact and v2 tests were used to evaluate
associations between histological subtypes, nuclear
grade and M/N score, as well as between clinico-
pathological variables and histological subtypes and
treatment received. For all data comparisons, results
were considered as statistically significant if P was
<0.05 based on two-sided tests. All calculations were
performed using GraphPad Prism version 8.0 (Graph-
Pad Inc., San Diego, CA, USA) and SPSS Statistics
version 23.0 package (SPSS Inc., Chicago, IL, USA).
Results
We analysed tumour samples of 192 patients who
had histopathologically confirmed diagnosis of eMPM
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Subtypes of epithelioid pleural mesothelioma 57
and for whom OS data were available. Median follow-
up was 423 days. Median age of patients was
65.0  10.8 years; 143 (74.5%) of the patients were
male. International Mesothelioma Interest Group
(IMIG) stage at the time of diagnosis was available for
126 patients, 48.4% (61 of 126) of whom had early
stage (IMIG I/II) disease, while 51.6% (65 of 126)
had advanced stage (IMIG III/IV) disease. Among the
192 eMPM cases, the solid variant was the most
common predominant pattern accounting for 52.1%
(100 if 192) of all samples, while 28.6% (55 of 192)
were predominantly tubulopapillary, 10.4% (20 of
192) trabecular, 4.7% (nine of 192) microcystic,
3.1% (six of 192) pleomorphic and 1.0% (two of
192) micropapillary. According to the nuclear grad-
ing system, 54.7% (105 of 192) were grouped in
grade 1, 32.3% (62 of 192) in grade 2 and 13.0%
(25 of 192) in grade 3. Based on the presence of
necrosis and mitotic counts, an M/N score of 0 was
assigned to 45.8% (88 of 192) of the cases, score 1
to 40.1% (77 of 192) and score 2 to 14.1% (27 of
192) of the samples (Table 1).
Next, we analysed the OS of each histological sub-
type of eMPM. Due to the very low number of
micropapillary variants (n = 2) in our cohort, those
were excluded from the survival analysis. We found
that tubulopapillary and microcystic subtypes associ-
ated with better prognosis (median OS 727 and
936 days, respectively), whereas patients with solid
and trabecular patterns had a shorter median OS
(397 and 394 days, respectively). The pleomorphic
eMPM patients had the shortest median OS of
173 days, which was significantly worse than med-
ian OS of tubulopapillary, microcystic and solid sub-
types (P < 0.0001, 0.0085 and 0.0277, respectively)
and showed a trend for worse outcomes in compar-
ison to predominant trabecular variant (P = 0.0906,
Figure 3A).
Due to the rarity of microcystic and trabecular pat-
terns the four subtypes, except for the pleomorphic
variant, were collapsed into two groups. Based on
their overlapping survival curves, specimens showing
a predominantly microcystic pattern were merged
with tubulopapillary variants, while trabecular
A B
D E
C
Figure 1. Histological subtypes of epithelioid malignant pleural mesothelioma (eMPM). A, Tubulopapillary pattern [haematoxylin and eosin
(H&E)]. B, Solid pattern (H&E). C, Trabecular pattern (H&E). D, Microcystic pattern (H&E). E, Pleomorphic features (H&E).
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patterns were merged with solid pattern tumours for
further analyses. The pleomorphic subtype was anal-
ysed as a separate group. In univariate analyses, we
found that patients with tubulopapillary/microcystic
features had a significantly better OS than patients
with solid/trabecular variants (medians 732 days ver-
sus 397 days, P = 0.003, Table 2, Figure 3B).
Pleomorphic tumours were associated with signifi-
cantly worse outcome when compared to solid/tra-
becular variants (median OS 173 days versus
397 days, P = 0.039 Table 2, Figure 3B). As the
pleomorphic variant showed a dramatically shorter
OS than all other subtypes in our cohort, and several
earlier studies suggested its exclusion from eMPM
based on its very poor prognosis, we did not include
it in our further survival analyses.20–23
Stage I/II disease was associated with a signifi-
cantly better OS than stage III/IV (medians 650 days
versus 421 days, P = 0.015, Table 2). The distribu-
tion of tubulopapillary/microcystic and solid/trabecu-
lar variants was similar among early (I/II) and
advanced stages (III/IV) of disease (P = 0.999, Sup-
porting information, Figure S1A). Early-stage cases
with tubulopapillary/microcystic features showed a
tendency for longer OS (Mantel–Cox test, P = 0.194;
Grehan–Breslow–Wilcoxon test P = 0.041; Support-
ing information, Figure S1B), while among the
advanced-stage patients the tubulopapillary/microcys-
tic variants were associated with a significantly
longer OS compared to the solid/trabecular variants
(P = 0.047, Supporting information, Figure S1C).
Patients with tumours of M/N scores 1, 2 and 3
had significantly different OS of 720 days, 386 days
(P = 0.0004) and 165 days (P = 0.0036), respec-
tively (Figure 4A, Table 2). There was no significant
difference in OS between nuclear grades 1 and 2.
However, patients with nuclear grade 3 had signifi-
cantly worse OS when compared to patients with
nuclear grade 2: median OS 123 versus 486 days
(P = 0.0002) (Figure 4B, Table 2).
Regarding the distribution of M/N scores as well as
nuclear grades among the histological subtypes we
A B
D E F
C
Figure 2. Mitosis, necrosis and nuclear grading in epithelioid malignant pleural mesothelioma (eMPM). A, Bipolar mitoses [arrowheads,
haematoxylin and eosin (H&E)]. B, Bipolar (arrowhead) and atypical (arrow) mitoses (H&E). C, Coagulative necrosis (H&E). D, Mild nuclear
atypia (H&E). E, Moderate nuclear atypia (H&E). F, Severe nuclear atypia (H&E).
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found a significant association of solid/trabecular pat-
terns with both higher M/N scores (P < 0.0001) and
higher nuclear grades (P = 0.007) in comparison to
tubulopapillary/microcystic variants (Figure 4C,D).
In multivariate analysis, including histological
subtype, M/N score and nuclear grading as parame-
ters, we found M/N score to be an independent
prognostic factor in our MPM cohort (Table 3). His-
tological subtype did not reach significance
(P = 0.095).
We analysed the impact on OS of each individual
factor – namely nuclear atypia, mitotic rate, presence
of necrosis – used to calculate composite grades.
Patients with tumours exhibiting mild atypia (median
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Figure 3. Histological subtypes and patient outcomes. A, Overall
survival (OS) of the five histological subtypes: tubulopapillary,
microcystic, solid, trabecular and pleomorphic (P = 0.0019, log-
rank test). B, OS of collapsed groups: solid/trabecular [hazard ratio
(HR) = Ref.], tubulopapillary/microcystic [HR = 0.57, 95% confi-
dence interval (CI) = 0.41–0.80] and the pleomorphic subtype
(HR = 4.72, 95% CI = 1.15–19.42). For all three curves:
P < 0.0001, log-rank test. [Colour figure can be viewed at wileyon-
linelibrary.com]
Table 1. Clinicopathological characteristics of the eMPM
patient cohort
Total
(n = 192)
Gender
Male 143
Female 49
Age (years)
Mean  SD 65.0  10.8
Histology
Solid 100
Tubulopapillary 55
Trabecular 20
Microcystic 9
Pleomorphic 6
Micropapillary 2
Nuclear atypia
Mild 13
Moderate 132
Severe 47
Mitotic count
Low (≤1) 117
Intermediate (2–4) 41
High (≥5) 34
Necrosis
Yes 94
No 98
Nuclear grade
1 105
2 62
3 25
M/N score
0 88
1 77
2 27
IMIG stage (NA = 66)
I/II 61
III/IV 65
NA, not available; SD, standard deviation; M/N, mitosis/necrosis;
eMPM, epithelioid malignant pleural mesothelioma; IMIG, Interna-
tional Mesothelioma Interest Group.
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OS 1197 days) had a significantly longer OS in com-
parison to those with moderate or severe atypia (me-
dian OS 501 days, P = 0.027 and 306 days,
P < 0.001, respectively, Table 2, Supporting informa-
tion, Figure S2A). High mitotic counts were associ-
ated with shorter median OS in comparison to low
mitotic rate (239 days, P < 0.001), while low and
intermediate mitotic counts did not show a significant
difference in median OS (545 and 501 days, respec-
tively, P = 0.470, Table 2, Supporting information,
Figure S2B). The presence of necrosis was also associ-
ated with a significantly shorter OS in comparison to
cases without necrosis (281 days versus 727 days,
respectively, P < 0.0001, Table 2, Supporting infor-
mation, Figure S2C).
We also performed a multivariate analysis of histo-
logical variants and individual components of the
composite scores. We found the presence of necrosis
to be a strong independent prognostic factor
(P < 0.0001, Supporting information, Table S1).
H I S T O P A T H O L O G I C A L A N A L Y S I S O F E M P M
S A M P L E S F R O M T H E T C G A C O H O R T
For external validation, we analysed an additional set
of eMPM samples derived from the TCGA for which
scanned H&E-stained sections were available. The
corresponding clinicopathological variables of these
55 patients are detailed in Supporting information,
Table S2. We found 50.9% (28 of 55) of the samples
to be of tubulopapillary pattern, 30.9% solid (17 of
55), 5.5% microcystic (three of 55), 5.5% trabecular
(three of 55) and 7.2% micropapillary (four of 55).
No sample with pleomorphic features was identified.
In agreement with the results obtained in our multi-
center MPM patient cohort, univariate analysis of the
OS data (Supporting information, Table S3) showed a
Table 2. Univariate survival analyses in the eMPM patient
cohort
Univariate analysis
OS
(days) HR (95% CI) P-value
Age
<70 years 495 0.92 (0.65–1.30) 0.619
≥70 years 463
Gender
Male 486 0.99 (0.69–1.44) 0.999
Female 469
Histology
Solid/trabecular 397 1 –
Tubulopap./microcyst. 732 0.58 (0.41–0.83) 0.003
Pleomorphic 173 2.65 (1.95–6.68) 0.039
Nuclear atypia
Mild 1197 1 –
Moderate 501 2.29 (1.32–3.97) 0.027
Severe 306 3.47 (1.88–6.42) <0.001
Mitotic count
Low (≤1) 545 1 –
Intermediate (2–4) 501 1.17 (0.75–1.87) 0.470
High (≥5) 239 2.48 (1.45–4.25) <0.001
Necrosis
Yes 281 2.38 (1.68–3.38) <0.0001
No 727
M/N score
0 720 1 –
1 383 2.01 (1.37–2.95) < 0.0001
2 165 2.61 (1.39–4.97) < 0.0001
Nuclear grade
1 555 1 –
2 486 1.10 (0.75–1.62) 0.531
3 123 3.75 (1.86–7.56) 0.0002
IMIG stage (NA = 66)
I/II 650 0.60 (0.39–0.91) 0.015
III/IV 421
Table 2. (Continued)
Univariate analysis
OS
(days) HR (95% CI) P-value
Treatment (NA = 76)
MMT 936 0.35 (0.23–0.55) <0.0001
CHT/BSC 340
NA, not available; SD, standard deviation; tubulopap., tubulopapil-
lary; microcyst., microcystic; M/N, mitosis/necrosis; OS, overall sur-
vival; eMPM, epithelioid malignant pleural mesothelioma; MMT,
multimodal therapy; CHT, chemotherapy; BSC, best supportive
care.
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significantly inferior OS associated with solid/trabec-
ular subtypes in comparison to tubulopapillary/mi-
crocystic patterns (median 406 days versus
795 days, P = 0.01, Figure 5C). Histological grading
was performed on 49 FFPE samples, while the six
samples for which fresh frozen samples were only
available were not included in grade analysis. The
solid/trabecular subtypes showed a significant asso-
ciation with higher M/N scores (P < 0.0001, Fig-
ure 5D). Nuclear grade 3 and M/N score 2 cases
were associated with significantly inferior OS than
nuclear grade 1 (P = 0.01) and M/N score 0
(P = 0.023), respectively (Figure 5A,B). However,
the low number of patients (n = 55) in the TCGA
validation cohort limited the feasibility of a multi-
variate analysis.
T H E I M P A C T O F M O R P H O L O G I C A L S U B T Y P E S I N
T H E M U L T I M O D A L T H E R A P E U T I C S E T T I N G
In order to identify whether tubulopapillary/microcys-
tic and solid/trabecular epithelioid subtypes are asso-
ciated with distinct outcomes after therapy, we
evaluated differences in OS of patients with the treat-
ment information available (n = 109, Supporting
information, Table S4). Forty per cent of patients (44
of 109) received multimodal therapy (MMT) consist-
ing of radical surgery plus chemo- and/or
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Figure 4. Mitosis/necrosis (M/N) score and nuclear grading. A, M/N score is a significant prognostic factor in eMPM. In comparison to M/N
score 0 [720 days, hazard ratio (HR) = Ref.], M/N score 1 [386 days, HR = 2.01, 95% confidence interval (CI) = 1.37–2.95, P < 0.0001,
log-rank test] and M/N score 2 (208 days, HR = 5.03, 95% CI = 2.43–10.46, P < 0.0001, log-rank test) are associated with shorter overall
survival (OS). B, Nuclear grading is a significant prognostic factor in epithelioid malignant pleural mesothelioma (eMPM). Nuclear grade 1
(555 days, HR = Ref.) is associated with longer OS in comparison to nuclear grade 3 (123 days, HR = 5.64, 95% CI = 2.69–11.83,
P = 0.0002, log-rank test), while nuclear grade 2 was not associated with significantly worse outcomes (486 days, HR = 1.10, 95%
CI = 0.75–1.62, P = 0.531, log-rank test). C, M/N score significantly associates with histological subtypes of eMPM, solid/trabecular variants
are associated with higher M/N scores (P < 0.0001, v2 test). D, Histological subtypes of eMPM show a significant association with nuclear
grades, solid/trabecular variants show a higher frequency of higher nuclear grades (P = 0.0008, v2 test). [Colour figure can be viewed at
wileyonlinelibrary.com]
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radiotherapy, while 60% (65 of 109) received
chemotherapy only (CHT) or best supportive care
(BSC). Accordingly, we stratified the cohort into four
subgroups based on solid/trabecular pattern eMPMs
versus tubulopapillary/microcystic pattern eMPMs
and MMT versus CHT/BSC treatment. We compared
the distribution of several clinicopathological vari-
ables between solid/trabecular and tubulopapillary/
microcystic subtypes treated with MMT or CHT/BSC
(Supporting information, Table S5). Among the two
subgroups with MMT there was no significant differ-
ence in patients’ age, gender, stage or the tumours’
nuclear grade and M/N scores. Comparing the two
subgroups with CHT/BSC we found that tubulopapil-
lary/microcystic tumours were significantly associated
with younger age, lower nuclear grades and M/N
scores, but we did not identify any significant differ-
ences in patients’ gender or stage.
Interestingly, we found that among patients who
received MMT those with tubulopapillary/microcystic
pattern MPMs showed a trend for OS superior to
patients with solid/trabecular pattern tumours
(HR = 2.29, 95% CI = 0.95–5.12, P = 0.066, Fig-
ure 6). Among those not receiving MMT there was
no significant difference in OS between the two main
groups of histological variants (HR = 1.16, 95%
CI = 0.65–2.07, P = 0.617, Figure 6). Furthermore,
both in the tubulopapillary/microcystic as well as in
the solid/trabecular subcohorts, MMT provided a sig-
nificant survival benefit (tubulopapillary/microcystic:
MMT versus CHT/BSC: HR = 2.67, 95% CI = 2.18–
3.08, P = 0.0006; solid/trabecular: MMT versus
CHT/BSC: HR = 1.77, 95% CI = 1.24–2.31,
P = 0.0018, Figure 6).
Discussion
In the current study, tumour samples from 192
patients with epithelioid MPM were re-analysed from
the archives of five large central European thoracic
centres. To the best of our knowledge, this is the sec-
ond largest study so far to evaluate the prognostic
role of different histological patterns of eMPM. More-
over, this is the first study to directly compare the
prognostic impact of morphological growth pattern,
the nuclear grade and the M/N score. The three main
histological types, epithelioid, biphasic and sarcoma-
toid, are recognised as distinct categories of MPM by
the most recent World Health Organisation classifica-
tion2 and are a mandatory part of the final diagno-
sis.4 According to the International Mesothelioma
Interest Group’s 2017 update, the histological pattern
of eMPMs is an optional part of a pathological report
but – in the light of emerging data – is currently
considered a potentially important prognostic fea-
ture,29 and is also recommended to be part of report-
ing by the 2020 guideline of the European Network
for Rare Adult Solid Cancers and the International
Association for the Study of Lung Cancer.28 The fre-
quency of the individual histological subtypes varies
substantially in the literature; nevertheless, we
observed their frequencies in our eMPM cohort to be
within the range of previous studies.20,22,23
In the daily practice of MPM diagnostics, the
amount of tissue available for histological work-up,
subtyping and grading is often an issue. In our opin-
ion, sampling heterogeneity might be an important
factor regarding variable subtype frequencies among
recent studies. Our cohort mainly consisted of surgi-
cal biopsies. However, was not pre-selected based on
sample size and included percutaneous core needle
biopsies. This is partly a limitation of this study but
also the reflection of a real-life situation from which
our samples come.
Regarding outcome, we found that among eMPMs
those of predominantly microcystic or tubulopapillary
pattern were associated with the longest OS. This
finding is similar to that of Brcic et al.23 and Alchami
et al.22 We found that the trabecular variant con-
ferred a relatively poor prognosis, similar to the solid
pattern. Regarding the trabecular variant, conflicting
data are available in the current literature.20,23
Table 3. Multivariate Cox regression analysis in the MPM
patient cohort
Multivariate analysis
HR 95% CI P-value
Histology
Solid/trabecular
tubulopap./microcyst.
0.723 0.50–1.06 0.095
M/N score
0
1
2
1.56 1.13–2.16 0.007
Nuclear grade
1
2
3
1.08 0.78–1.48 0.648
CI, confidence interval; HR, hazard ratio; tubulopap., tubulopapil-
lary; microcyst., microcystic; M/N, mitosis/necrosis; MPM, malig-
nant pleural mesothelioma.
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Furthermore, we were able to confirm the previously
reported dismal prognosis of MPM exhibiting pleo-
morphic features.20–23 Based on overlapping survival
curves, we merged the tubulopapillary and microcys-
tic variants, as well as solid and trabecular variants.
We found these two groups to have significantly dif-
ferent OS. In an external validation cohort consisting
of 55 digitised eMPM sections of the TCGA project we
confirmed a similar significant difference in OS
between these two groups.
The newly proposed M/N score aiming to further
stratify patients with eMPM was a robust marker in
our patient population. In multivariate analysis, we
found M/N score to be the single independent
prognostic factor. On analysing the individual compo-
nents of the composite grades, we identified the pres-
ence of necrosis to be an independent factor defining
prognosis. This result may be partially explained by
the significant association we observed between solid/
trabecular pattern and higher M/N scores and higher
nuclear grades. While nuclear grade 3 tumours
showed a significantly shorter OS, we found no signif-
icant OS difference between nuclear grade 1 and 2
tumours. This finding further supports the new EUR-
ACAN/IASLC proposal on the use of preferentially
two-tier grading of eMPM.28
Predominant histological subtypes30 of invasive lung
adenocarcinomas have been shown to have a stage-
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independent prognostic impact31 and to be of predictive
value for determining the patients’ subgroup that might
benefit from adjuvant chemotherapy after complete sur-
gical resection.32 In our mesothelioma subcohort analy-
sis, we investigated if histological patterns might be a
useful marker for identifying patients who might benefit
more from a more aggressive treatment approach. In
this regard, we found a more pronounced OS difference
between patients receiving multimodal therapy versus
chemotherapy only or best supportive care in case of
tubulopapillary/microcystic compared to solid/trabecu-
lar MPM. These findings suggest that histological sub-
types might be useful to risk-stratify eMPM patients
prior to therapeutic decisions in multimodal treatment
settings. Nevertheless, this observation needs further
independent confirmation and prospective validation.
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Figure S1. (A) Distribution of histologic variants
among early and advanced disease stage patients.
(P = 0.999, Fisher’s exact test). (B) OS of tubulopapil-
lary/microcystic and solid/trabecular histologic sub-
types in the early stage subgroup of patients (median
OS: 897 days, HR = Ref. versus median OS: 510 days,
HR = 1.55, 95% CI [0.80–2.98], P = 0.194 by Man-
tel-Cox test; P = 0.041 by Gehan-Breslow-Wilcoxon
test) (C) OS of tubulopapillary/microcystic and solid/tra-
becular histologic subtypes in the advanced stage sub-
group of patients (median OS: 660 days, HR = Ref.
versus median OS: 401 days, HR = 1.75, 95% CI
[1.00–3.06], P = 0.047, Mantel-Cox test).
Figure S2. (A) OS of tumors exhibiting mild
(HR = Ref.), moderate (HR = 2.29, 95% CI [1.32–
3.97], P = 0.027) and severe nuclear atypia
(HR = 3.47, 95% CI [1.88–6.42], P < 0.001). (B) OS
and mitotic counts. Low (HR = Ref.) and intermediate
(HR = 1.17, 95% CI [0.75–1.87], P = 0.470) numbers
of mitotic figures are associatedwith a significantly better
OS in comparison to high mitotic counts (HR = 2.48,
95% CI [1.45–4.25], P < 0.001) (C) The presence of
necrosis is associated with significantly shorter OS
(HR = 2.38, 95% CI [1.68–3.38], P < 0.0001).
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